Drug intelligence / Profile preview

LTX-328

Development stage: Discontinued
Lead developer: Lytix Biopharma
Modality: Peptides
Administration: Intratumoral

Overview

LTX-328 is a synthetic peptide designed as a non-lytic, non-oncolytic control peptide, structurally related to the oncolytic peptide LTX-302, but unlike LTX-302, LTX-328 does not exhibit cytotoxic or anticancer activity in preclinical models. It has been used primarily as a negative control peptide in experimental studies investigating antimicrobial or anticancer peptides. LTX-328 is a 9-mer peptide composed to mimic certain physicochemical properties of its parent peptide but lacks the oncolytic, immunogenic, or cytotoxic effects of other related peptides in vitro and in vivo[1].

Beyond the preview

Go deeper on LTX-328.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LTX-328.

Explore the full profile